Citigroup Portfolio holdings
Citigroup Inc., formed in 1998 through the landmark merger of Citicorp and Travelers Group, with roots tracing back to the 1812 founding of City Bank of New York, is a global financial powerhouse headquartered in New York City, managing trillions in assets. Operating in over 160 countries, Citigroup offers a broad spectrum of services, including consumer banking (via Citibank), investment banking, wealth management, and trading, serving millions of retail customers and major corporations, governments, and institutions worldwide. Under CEO Jane Fraser since 2021—the first woman to lead a major U.S. bank—Citigroup has focused on streamlining operations, exiting consumer banking in 13 markets to bolster its institutional and wealth management focus, while navigating post-2008 regulatory scrutiny and fines. Known for its vast global footprint and resilience through crises, Citigroup remains a key player in international finance, blending retail accessibility with high-stakes capital markets expertise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jefferies Financial Group
JEF
|
+$460M |
| 2 |
Palo Alto Networks
PANW
|
+$363M |
| 3 |
State Street SPDR S&P Biotech ETF
XBI
|
+$330M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$291M |
| 5 |
iShares China Large-Cap ETF
FXI
|
+$272M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Caterpillar
CAT
|
+$755M |
| 2 |
Microsoft
MSFT
|
+$674M |
| 3 |
Apple
AAPL
|
+$642M |
| 4 |
Flutter Entertainment
FLUT
|
+$572M |
| 5 |
NVIDIA
NVDA
|
+$512M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.64% |
| 2 | Consumer Discretionary | 7.06% |
| 3 | Financials | 6.47% |
| 4 | Healthcare | 4.72% |
| 5 | Communication Services | 4.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3826
Evolv Technologies
EVLV
$998M
| $443K | ﹤0.01% |
112,069
+17,312
| +18% | +$60.7K |
|
3827
i3 Verticals
IIIV
$419M
| $442K | ﹤0.01% |
19,189
+2,581
| +16% | +$60.5K |
|
|
NYAX
3828
Nayax
NYAX
$2.54B
| $440K | ﹤0.01% |
15,001
+14,996
| +299,920% | +$413K |
|
|
DHC
3829
Diversified Healthcare Trust
DHC
$2.15B
| $440K | ﹤0.01% |
191,349
+17,043
| +10% | +$50.2K |
|
3830
Taysha Gene Therapies
TSHA
$1.61B
| $438K | ﹤0.01% |
253,292
+120,680
| +91% | +$250K |
|
3831
Omeros
OMER
$845M
| $436K | ﹤0.01% |
44,175
+3,128
| +8% | +$21.5K |
|
3832
CALL
uniQure
QURE
$2.78B
| $436K | ﹤0.01% |
24,700
-19,900
| -45% | -$172K |
|
|
3833
PUT
uniQure
QURE
$2.78B
| $436K | ﹤0.01% |
24,700
-19,900
| -45% | -$172K |
|
3834
Sana Biotechnology
SANA
$882M
| $436K | ﹤0.01% |
267,510
+162,365
| +154% | +$484K |
|
|
UPB
3835
Upstream Bio Inc
UPB
$349M
| $436K | ﹤0.01% |
+26,504
| New | +$592K |
|
3836
PACS Group
PACS
$7.35B
| $435K | ﹤0.01% |
33,206
+4,241
| +15% | +$109K |
|
|
RPC
3837
Ridgepost Capital
RPC
$926M
| $435K | ﹤0.01% |
34,521
+3,706
| +12% | +$45.2K |
|
3838
PUT
Pinterest
PINS
$13.7B
| $435K | ﹤0.01% |
15,000
-135,000
| -90% | -$4.24M |
|
3839
Pacific Biosciences
PACB
$435M
| $435K | ﹤0.01% |
237,691
+8,591
| +4% | +$16.8K |
|
3840
Standard BioTools
LAB
$342M
| $434K | ﹤0.01% |
247,855
+17,230
| +7% | +$32.1K |
|
|
SRDX
3841
DELISTED
Surmodics
SRDX
| $433K | ﹤0.01% |
10,928
-11,083
| -50% | -$431K |
|
3842
Real Brokerage
REAX
$360M
| $432K | ﹤0.01% |
93,827
+24,371
| +35% | +$128K |
|
3843
ClearPoint Neuro
CLPT
$424M
| $431K | ﹤0.01% |
28,049
-62,519
| -69% | -$810K |
|
3844
Denison Mines
DNN
$2.43B
| $431K | ﹤0.01% |
237,713
+36,352
| +18% | +$76.5K |
|
3845
Acco Brands
ACCO
$399M
| $430K | ﹤0.01% |
81,993
+9,612
| +13% | +$53.4K |
|
3846
Vanguard Russell 1000 ETF
VONE
$8.09B
| $430K | ﹤0.01% |
1,613
| – | – |
|
|
FPI
3847
Farmland Partners
FPI
$415M
| $428K | ﹤0.01% |
36,417
+4,211
| +13% | +$49.4K |
|
3848
Zevra Therapeutics
ZVRA
$578M
| $428K | ﹤0.01% |
51,284
+20,753
| +68% | +$177K |
|
3849
Excelerate Energy
EE
$1.19B
| $426K | ﹤0.01% |
14,082
+1,614
| +13% | +$43.7K |
|
3850
Invesco FTSE RAFI Developed Markets ex-US ETF
PXF
$2.83B
| $425K | ﹤0.01% |
8,881
+71
| +0.8% | +$3.53K |
|
Similar funds
Citigroup's Q4 2024 Portfolio in Review
As of Q4 2024, Citigroup held 6,077 positions worth $169B, down 2.4% from $173B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Citigroup withdrew a net $7.85B in Q4 2024, closing 263 positions and reducing 1,533 holdings. Its most notable exit was Stericycle Inc, an estimated $125M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Citigroup opened a new position in T-Rex 2X Long MSTR Daily Target ETF worth $19M.
- Citigroup's largest Q4 2024 buy was T-Rex 2X Long MSTR Daily Target ETF: 249,467 shares worth $19M.
- Citigroup added most to Jefferies Financial Group in Q4 2024, an estimated $460M increase.
- Citigroup's biggest Q4 2024 reduction was Caterpillar, cutting an estimated $755M.
- Citigroup fully exited Stericycle Inc in Q4 2024, selling an estimated $125M.
- Citigroup's ten largest holdings make up 21% of its $169B portfolio in Q4 2024.
- Citigroup opened 429 new positions and closed 263 in Q4 2024.
- Citigroup's portfolio value fell 2.4% quarter-over-quarter to $169B.
Based on Citigroup's 13F filing for Q4 2024, filed 12 Feb 2025.